Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury

Sponsor
Chen Wei Ren, MD
Study ID
NCT02001363
Status
Unknown

Conditions

  • Acute Myocardial Infarction

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide (Novo Nordisk, Bagsværd, Denmark) — DRUG
    once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
  • liraglutide placebo (Novo Nordisk) — DRUG
    once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days

Study Details

The investigators planned to research the cardioprotective effects of intravenous liraglutide on reperfusion injury.

Key Dates

Start date
Nov 30, 2013
Status verified
Feb 2016
Primary completion
Mar 31, 2016
Completion
Mar 31, 2016

Study Design

Enrollment
90 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: liraglutide
    drug: liraglutide (Novo Nordisk, Bagsværd, Denmark) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
  • Placebo Comparator: liraglutide placebo
    drug:liraglutide placebo (Novo Nordisk) duration:7 days(from admission (primary percutaneous coronary intervention) to discharge) the intervention:once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days

Primary Outcome Measure

the salvage index measured by cardiac magnetic resonance [ Time Frame: 3 months after primary percutaneous coronary intervention ]

Central Contacts

Related Studies